The quest to find new drugs to treat Alzheimer's just suffered another blow


Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting disease. Accera's AC-1204 failed to induce a statistically significant improvement in symptoms versus a placebo in patients with a mild-to-moderate form of the disease, the company said.



from Biotech News